Mr. Am Gill reports

BIOSENTA ANNOUNCES SUCCESSFUL LAUNCH OF BENCH SCALE PRODUCTION PLANT AND EXCEEDING EXPECTATIONS OF TRI-FILLER PARTICLE ENCAPSULATION TECHNOLOGY

Biosenta Inc. has made a significant milestone in its technological and operational advancements with the successful construction and operation of a bench-scale production plant. The results from this production not only surpassed the company's expectations, but also showcased that its patented Tri-Filler antimicrobial technology is ready for accelerated development and scaling toward industrial manufacturing applications.

Operational success and optimizations

Biosenta has successfully constructed and commenced operations of a bench-scale production plant, showcasing the company's capability to produce up to 15 kilograms of Tri-Filler daily. This marks a significant scale-up from its previous capacity, which was limited to smaller quantities for lab testing purposes only.

Chief executive officer's perspective

"This is an amazing achievement by Dr. Maen Husein and group. The optimized particles are now being tested in industrial manufacturing processes," says Am Gill, chief executive officer of Biosenta. This development is not just a step forward in antimicrobial technology but also a testament to our team's dedication and innovative spirit.

Promising results and future directions

According to Dr. Maen Husein: "The initial runs of Tri-Filler have delivered beyond expectations, with particle quality surpassing pre-established benchmarks. These results validate both the antimicrobial efficacy of the particles and the design of the manufacturing unit." Next steps involve operation of the bench scale plant, aiming to produce sufficient Tri-Filler for pilot runs in various industrial processes such as coatings, concrete, drywall, plastics and other vast materials in the construction industry. Plans for a commercial scale plant will follow.

Research collaboration with the University of Calgary

In partnership with the University of Calgary, further investigations will assess the performance of the bench-scale plant against diverse input grades. This collaboration is crucial for refining the industrial scale plant's optimization, paving the way for broader commercial applications of Tri-Filler technology.

Looking ahead

The construction of an industrial scale-up plant is under active consideration, with further details and timelines to be shared. This move will significantly enhance its production capabilities and impact across multiple industries.

About Biosenta Inc.

Biosenta is dedicated to the discovery, development and commercialization of innovative antimicrobial products derived from its proprietary Tri-Filler technology.

We seek Safe Harbor.